Vasilis Liberis

Suggest Changes
We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
OBJECTIVES Trastuzumab, an antic-erbB-2 monoclonal antibody, has become a standard component of chemotherapy for c-erbB-2-positive advanced breast carcinoma. Despite the experimental evidence of its(More)
  • 1